Drug Trial Radar · NCT05804045
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
94
Actual
Start
Apr 27, 2023
Primary completion
Sep 23, 2024
Study completion Jun 2028
Sponsor
- Lead sponsor
- Abbisko Therapeutics Co, LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in patients with Tenosynovial Giant Cell Tumor (TGCT). The main questions it aims to answer are: * Whether the Pimicotinib(ABSK021) works well in patients with TGCT. * Whether the Pimicotinib(ABSK021) is safe in patients with TGCT. Participants will be asked to complete the study procedures: * Receive the administration of Pimicotinib(ABSK021) or placebo (a placebo is a look-alike substance that contains no active drug) about 24 weeks in study part 1. * Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2. * Receive the administration of Pimicotinib(ABSK021) till study end in study part 3. * Complete the study procedures speficied in the protocol, which is guided by researchers.
Conditions
- Tenosynovial Giant Cell Tumor
- Pigmented Villonodular Synovitis
- Giant Cell Tumor of Tendon Sheath
Interventions
Pimicotinib(ABSK021)Drug
capsule
PlaceboDrug
capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Baseline to Week 25
Locations
40 sites in 7 countries. Site status is shown where the registry gives one.
Precision NextGen Oncology
Beverly Hills, California
Duke University Medical Center
Durham, California
Henry Ford Health System
Detroit, Michigan
Roswell Park Comprehensive Cancer Center
Buffalo, New York
The Cleveland Clinic Foundation
Cleveland, Ohio
The Ohio State University
Columbus, Ohio
The University of Texas M.D. Anderson Cancer Center
Houston, Texas
Fred Hutchinson Cancer Center
Seattle, Washington
McGill University Health Center
Montreal, Canada
Princess Margaret Cancer Center
Toronto, Canada
Beijing Jishuitan Hospital
Beijing, China
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
Peking University People's Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China
Henan Cancer Hospital
Zhengzhou, Henan, China
The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture
Enshi, Hubei, China
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Hunan Provincial People's Hospital
Changsha, Hunan, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Nanjing Drum Tower hospital
Nanjing, Jiangsu, China
Liaoning Cancer Hospital&Institute
Shenyang, Liaoning, China
Weifang People's Hospital
Weifang, Shandong, China
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
The Second Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
Xi'an Honghui Hospital
Xi’an, Shanxi, China
West China Hospital Sichuan University
Chengdu, Wuhan, China
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
IRCCS Istituto Ortopedico Rizzoli
Bologna, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Ospedale di Prato
Prato, Italy
Leiden University Medical Center
Leiden, Netherlands
Maria Sklodowska-Curie National Research Institute of Oncology
Warsaw, Poland
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Fundacion Jimenez Diaz
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.